|
Name |
Asperentin-8-methyl ether
|
Molecular Formula | C17H22O5 | |
IUPAC Name* |
6-hydroxy-8-methoxy-3-[[(2R,6S)-6-methyloxan-2-yl]methyl]-3,4-dihydroisochromen-1-one
|
|
SMILES |
C[C@H]1CCC[C@@H](O1)CC2CC3=C(C(=CC(=C3)O)OC)C(=O)O2
|
|
InChI |
InChI=1S/C17H22O5/c1-10-4-3-5-13(21-10)9-14-7-11-6-12(18)8-15(20-2)16(11)17(19)22-14/h6,8,10,13-14,18H,3-5,7,9H2,1-2H3/t10-,13+,14?/m0/s1
|
|
InChIKey |
COFDRZBGPVKKJQ-CMVMAMJTSA-N
|
|
Synonyms |
asperentin-8-methyl ether; asperentin 8-O-methylether; cladosporin 8-O-methylether; CHEBI:68703; Q27137123; 6-hydroxy-8-methoxy-3-{[(2R,6S)-6-methyltetrahydro-2H-pyran-2-yl]methyl}-3,4-dihydro-1H-isochromen-1-one
|
|
CAS | NA | |
PubChem CID | 71728345 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 306.4 | ALogp: | 3.0 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.864 |
Caco-2 Permeability: | -4.665 | MDCK Permeability: | 0.00005470 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.014 |
Blood-Brain-Barrier Penetration (BBB): | 0.518 | Plasma Protein Binding (PPB): | 68.95% |
Volume Distribution (VD): | 0.964 | Fu: | 8.68% |
CYP1A2-inhibitor: | 0.437 | CYP1A2-substrate: | 0.424 |
CYP2C19-inhibitor: | 0.246 | CYP2C19-substrate: | 0.768 |
CYP2C9-inhibitor: | 0.082 | CYP2C9-substrate: | 0.902 |
CYP2D6-inhibitor: | 0.245 | CYP2D6-substrate: | 0.793 |
CYP3A4-inhibitor: | 0.621 | CYP3A4-substrate: | 0.224 |
Clearance (CL): | 13.125 | Half-life (T1/2): | 0.516 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.807 |
Drug-inuced Liver Injury (DILI): | 0.705 | AMES Toxicity: | 0.308 |
Rat Oral Acute Toxicity: | 0.017 | Maximum Recommended Daily Dose: | 0.976 |
Skin Sensitization: | 0.91 | Carcinogencity: | 0.903 |
Eye Corrosion: | 0.014 | Eye Irritation: | 0.579 |
Respiratory Toxicity: | 0.72 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003280 | 0.779 | D0X5KF | 0.289 | ||||
ENC002387 | 0.585 | D07MGA | 0.281 | ||||
ENC003043 | 0.577 | D0T6RC | 0.276 | ||||
ENC003297 | 0.557 | D09PJX | 0.273 | ||||
ENC002298 | 0.532 | D03SKD | 0.270 | ||||
ENC005004 | 0.532 | D0L1JW | 0.268 | ||||
ENC003715 | 0.519 | D0NS6H | 0.265 | ||||
ENC005001 | 0.500 | D00ZFP | 0.253 | ||||
ENC003973 | 0.494 | D04TDQ | 0.246 | ||||
ENC003318 | 0.483 | D04JHN | 0.245 |